Cargando…
HSV Recombinant Vectors for Gene Therapy
The very deep knowledge acquired on the genetics and molecular biology of herpes simplex virus (HSV), has allowed the development of potential replication-competent and replication-defective vectors for several applications in human healthcare. These include delivery and expression of human genes to...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Open
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936037/ https://www.ncbi.nlm.nih.gov/pubmed/20835362 http://dx.doi.org/10.2174/1874357901004010123 |
_version_ | 1782186443274190848 |
---|---|
author | Manservigi, Roberto Argnani, Rafaela Marconi, Peggy |
author_facet | Manservigi, Roberto Argnani, Rafaela Marconi, Peggy |
author_sort | Manservigi, Roberto |
collection | PubMed |
description | The very deep knowledge acquired on the genetics and molecular biology of herpes simplex virus (HSV), has allowed the development of potential replication-competent and replication-defective vectors for several applications in human healthcare. These include delivery and expression of human genes to cells of the nervous systems, selective destruction of cancer cells, prophylaxis against infection with HSV or other infectious diseases, and targeted infection to specific tissues or organs. Replication-defective recombinant vectors are non-toxic gene transfer tools that preserve most of the neurotropic features of wild type HSV-1, particularly the ability to express genes after having established latent infections, and are thus proficient candidates for therapeutic gene transfer settings in neurons. A replication-defective HSV vector for the treatment of pain has recently entered in phase 1 clinical trial. Replication-competent (oncolytic) vectors are becoming a suitable and powerful tool to eradicate brain tumours due to their ability to replicate and spread only within the tumour mass, and have reached phase II/III clinical trials in some cases. The progress in understanding the host immune response induced by the vector is also improving the use of HSV as a vaccine vector against both HSV infection and other pathogens. This review briefly summarizes the obstacle encountered in the delivery of HSV vectors and examines the various strategies developed or proposed to overcome such challenges. |
format | Text |
id | pubmed-2936037 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Bentham Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-29360372010-09-10 HSV Recombinant Vectors for Gene Therapy Manservigi, Roberto Argnani, Rafaela Marconi, Peggy Open Virol J Article The very deep knowledge acquired on the genetics and molecular biology of herpes simplex virus (HSV), has allowed the development of potential replication-competent and replication-defective vectors for several applications in human healthcare. These include delivery and expression of human genes to cells of the nervous systems, selective destruction of cancer cells, prophylaxis against infection with HSV or other infectious diseases, and targeted infection to specific tissues or organs. Replication-defective recombinant vectors are non-toxic gene transfer tools that preserve most of the neurotropic features of wild type HSV-1, particularly the ability to express genes after having established latent infections, and are thus proficient candidates for therapeutic gene transfer settings in neurons. A replication-defective HSV vector for the treatment of pain has recently entered in phase 1 clinical trial. Replication-competent (oncolytic) vectors are becoming a suitable and powerful tool to eradicate brain tumours due to their ability to replicate and spread only within the tumour mass, and have reached phase II/III clinical trials in some cases. The progress in understanding the host immune response induced by the vector is also improving the use of HSV as a vaccine vector against both HSV infection and other pathogens. This review briefly summarizes the obstacle encountered in the delivery of HSV vectors and examines the various strategies developed or proposed to overcome such challenges. Bentham Open 2010-06-18 /pmc/articles/PMC2936037/ /pubmed/20835362 http://dx.doi.org/10.2174/1874357901004010123 Text en © Manservigi et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Manservigi, Roberto Argnani, Rafaela Marconi, Peggy HSV Recombinant Vectors for Gene Therapy |
title | HSV Recombinant Vectors for Gene Therapy |
title_full | HSV Recombinant Vectors for Gene Therapy |
title_fullStr | HSV Recombinant Vectors for Gene Therapy |
title_full_unstemmed | HSV Recombinant Vectors for Gene Therapy |
title_short | HSV Recombinant Vectors for Gene Therapy |
title_sort | hsv recombinant vectors for gene therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936037/ https://www.ncbi.nlm.nih.gov/pubmed/20835362 http://dx.doi.org/10.2174/1874357901004010123 |
work_keys_str_mv | AT manservigiroberto hsvrecombinantvectorsforgenetherapy AT argnanirafaela hsvrecombinantvectorsforgenetherapy AT marconipeggy hsvrecombinantvectorsforgenetherapy |